nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP2E1—Dacarbazine—pancreatic cancer	0.0502	0.0708	CbGbCtD
Ondansetron—KCNH2—Sunitinib—pancreatic cancer	0.0453	0.0639	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0413	0.0583	CbGbCtD
Ondansetron—CYP3A7—Tamoxifen—pancreatic cancer	0.0413	0.0583	CbGbCtD
Ondansetron—CYP2E1—Tamoxifen—pancreatic cancer	0.0399	0.0563	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0317	0.0448	CbGbCtD
Ondansetron—CYP3A7—Irinotecan—pancreatic cancer	0.0317	0.0448	CbGbCtD
Ondansetron—CYP3A5—Tamoxifen—pancreatic cancer	0.031	0.0438	CbGbCtD
Ondansetron—CYP1A2—Dacarbazine—pancreatic cancer	0.029	0.0409	CbGbCtD
Ondansetron—CYP3A5—Erlotinib—pancreatic cancer	0.0264	0.0372	CbGbCtD
Ondansetron—CYP3A5—Irinotecan—pancreatic cancer	0.0238	0.0336	CbGbCtD
Ondansetron—CYP3A7—Docetaxel—pancreatic cancer	0.0233	0.0328	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0233	0.0328	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.0232	0.0327	CbGbCtD
Ondansetron—CYP3A7—Sunitinib—pancreatic cancer	0.0232	0.0327	CbGbCtD
Ondansetron—CYP1A2—Tamoxifen—pancreatic cancer	0.0231	0.0326	CbGbCtD
Ondansetron—CYP2C9—Tamoxifen—pancreatic cancer	0.0208	0.0293	CbGbCtD
Ondansetron—CYP1A2—Erlotinib—pancreatic cancer	0.0196	0.0277	CbGbCtD
Ondansetron—CYP2D6—Tamoxifen—pancreatic cancer	0.019	0.0268	CbGbCtD
Ondansetron—CYP3A5—Docetaxel—pancreatic cancer	0.0174	0.0246	CbGbCtD
Ondansetron—CYP3A5—Sunitinib—pancreatic cancer	0.0174	0.0245	CbGbCtD
Ondansetron—CYP1A2—Fluorouracil—pancreatic cancer	0.017	0.024	CbGbCtD
Ondansetron—CYP2D6—Erlotinib—pancreatic cancer	0.0162	0.0228	CbGbCtD
Ondansetron—CYP2C9—Fluorouracil—pancreatic cancer	0.0153	0.0216	CbGbCtD
Ondansetron—HTR3A—enteric nervous system—pancreatic cancer	0.013	0.601	CbGeAlD
Ondansetron—CYP3A4—Tamoxifen—pancreatic cancer	0.0121	0.0171	CbGbCtD
Ondansetron—CYP3A4—Erlotinib—pancreatic cancer	0.0103	0.0145	CbGbCtD
Ondansetron—CYP3A4—Irinotecan—pancreatic cancer	0.00928	0.0131	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—pancreatic cancer	0.00798	0.0113	CbGbCtD
Ondansetron—CYP3A4—Docetaxel—pancreatic cancer	0.0068	0.0096	CbGbCtD
Ondansetron—CYP3A4—Sunitinib—pancreatic cancer	0.00677	0.00956	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—pancreatic cancer	0.00507	0.00716	CbGbCtD
Ondansetron—SLC47A2—digestive system—pancreatic cancer	0.00209	0.0968	CbGeAlD
Ondansetron—HTR3A—islet of Langerhans—pancreatic cancer	0.00124	0.0574	CbGeAlD
Ondansetron—KCNH2—islet of Langerhans—pancreatic cancer	0.000749	0.0346	CbGeAlD
Ondansetron—HTR3A—digestive system—pancreatic cancer	0.000746	0.0345	CbGeAlD
Ondansetron—SLC47A1—digestive system—pancreatic cancer	0.000733	0.0339	CbGeAlD
Ondansetron—CYP3A5—islet of Langerhans—pancreatic cancer	0.000618	0.0286	CbGeAlD
Ondansetron—CYP3A5—pancreas—pancreatic cancer	0.000435	0.0201	CbGeAlD
Ondansetron—CYP1A2—digestive system—pancreatic cancer	0.000385	0.0178	CbGeAlD
Ondansetron—CYP3A5—digestive system—pancreatic cancer	0.000371	0.0172	CbGeAlD
Ondansetron—CYP2C9—digestive system—pancreatic cancer	0.000365	0.0169	CbGeAlD
Ondansetron—CYP2E1—digestive system—pancreatic cancer	0.000346	0.016	CbGeAlD
Ondansetron—CYP3A4—digestive system—pancreatic cancer	0.000279	0.0129	CbGeAlD
Ondansetron—CYP2D6—digestive system—pancreatic cancer	0.000274	0.0127	CbGeAlD
Ondansetron—Dizziness—Erlotinib—pancreatic cancer	0.000255	0.00134	CcSEcCtD
Ondansetron—Erythema multiforme—Docetaxel—pancreatic cancer	0.000253	0.00133	CcSEcCtD
Ondansetron—Hypotension—Gemcitabine—pancreatic cancer	0.00025	0.00131	CcSEcCtD
Ondansetron—Eye disorder—Docetaxel—pancreatic cancer	0.00025	0.00131	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.000249	0.00131	CcSEcCtD
Ondansetron—Cardiac disorder—Docetaxel—pancreatic cancer	0.000248	0.0013	CcSEcCtD
Ondansetron—Flushing—Docetaxel—pancreatic cancer	0.000248	0.0013	CcSEcCtD
Ondansetron—Vomiting—Tamoxifen—pancreatic cancer	0.000248	0.0013	CcSEcCtD
Ondansetron—Paraesthesia—Irinotecan—pancreatic cancer	0.000247	0.0013	CcSEcCtD
Ondansetron—Hypotension—Fluorouracil—pancreatic cancer	0.000246	0.00129	CcSEcCtD
Ondansetron—Hypersensitivity—Sunitinib—pancreatic cancer	0.000246	0.00129	CcSEcCtD
Ondansetron—Rash—Tamoxifen—pancreatic cancer	0.000245	0.00129	CcSEcCtD
Ondansetron—Dermatitis—Tamoxifen—pancreatic cancer	0.000245	0.00129	CcSEcCtD
Ondansetron—Vomiting—Erlotinib—pancreatic cancer	0.000245	0.00129	CcSEcCtD
Ondansetron—Dyspnoea—Irinotecan—pancreatic cancer	0.000245	0.00129	CcSEcCtD
Ondansetron—Somnolence—Irinotecan—pancreatic cancer	0.000244	0.00128	CcSEcCtD
Ondansetron—Headache—Tamoxifen—pancreatic cancer	0.000244	0.00128	CcSEcCtD
Ondansetron—Rash—Erlotinib—pancreatic cancer	0.000243	0.00128	CcSEcCtD
Ondansetron—Dermatitis—Erlotinib—pancreatic cancer	0.000243	0.00127	CcSEcCtD
Ondansetron—Angiopathy—Docetaxel—pancreatic cancer	0.000242	0.00127	CcSEcCtD
Ondansetron—Immune system disorder—Docetaxel—pancreatic cancer	0.000241	0.00127	CcSEcCtD
Ondansetron—Headache—Erlotinib—pancreatic cancer	0.000241	0.00127	CcSEcCtD
Ondansetron—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000241	0.00127	CcSEcCtD
Ondansetron—Liver function test abnormal—Epirubicin—pancreatic cancer	0.000241	0.00126	CcSEcCtD
Ondansetron—Paraesthesia—Gemcitabine—pancreatic cancer	0.00024	0.00126	CcSEcCtD
Ondansetron—Chills—Docetaxel—pancreatic cancer	0.00024	0.00126	CcSEcCtD
Ondansetron—Asthenia—Sunitinib—pancreatic cancer	0.000239	0.00126	CcSEcCtD
Ondansetron—Arrhythmia—Docetaxel—pancreatic cancer	0.000239	0.00125	CcSEcCtD
Ondansetron—Dyspnoea—Gemcitabine—pancreatic cancer	0.000239	0.00125	CcSEcCtD
Ondansetron—Somnolence—Gemcitabine—pancreatic cancer	0.000238	0.00125	CcSEcCtD
Ondansetron—Hypokalaemia—Epirubicin—pancreatic cancer	0.000237	0.00125	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000237	0.00125	CcSEcCtD
Ondansetron—Fatigue—Irinotecan—pancreatic cancer	0.000237	0.00124	CcSEcCtD
Ondansetron—Paraesthesia—Fluorouracil—pancreatic cancer	0.000236	0.00124	CcSEcCtD
Ondansetron—Pruritus—Sunitinib—pancreatic cancer	0.000236	0.00124	CcSEcCtD
Ondansetron—Pain—Irinotecan—pancreatic cancer	0.000235	0.00123	CcSEcCtD
Ondansetron—Constipation—Irinotecan—pancreatic cancer	0.000235	0.00123	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000235	0.00123	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000235	0.00123	CcSEcCtD
Ondansetron—Dyspnoea—Fluorouracil—pancreatic cancer	0.000235	0.00123	CcSEcCtD
Ondansetron—Somnolence—Fluorouracil—pancreatic cancer	0.000234	0.00123	CcSEcCtD
Ondansetron—Erythema—Docetaxel—pancreatic cancer	0.000233	0.00122	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000231	0.00121	CcSEcCtD
Ondansetron—Fatigue—Gemcitabine—pancreatic cancer	0.000231	0.00121	CcSEcCtD
Ondansetron—Pain—Gemcitabine—pancreatic cancer	0.000229	0.0012	CcSEcCtD
Ondansetron—Constipation—Gemcitabine—pancreatic cancer	0.000229	0.0012	CcSEcCtD
Ondansetron—Diarrhoea—Sunitinib—pancreatic cancer	0.000228	0.0012	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000227	0.00119	CcSEcCtD
Ondansetron—Feeling abnormal—Irinotecan—pancreatic cancer	0.000226	0.00119	CcSEcCtD
Ondansetron—Asthma—Epirubicin—pancreatic cancer	0.000225	0.00118	CcSEcCtD
Ondansetron—Pain—Fluorouracil—pancreatic cancer	0.000225	0.00118	CcSEcCtD
Ondansetron—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000225	0.00118	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000223	0.00117	CcSEcCtD
Ondansetron—Dizziness—Sunitinib—pancreatic cancer	0.00022	0.00116	CcSEcCtD
Ondansetron—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00022	0.00116	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000219	0.00115	CcSEcCtD
Ondansetron—Angina pectoris—Epirubicin—pancreatic cancer	0.000219	0.00115	CcSEcCtD
Ondansetron—Body temperature increased—Irinotecan—pancreatic cancer	0.000217	0.00114	CcSEcCtD
Ondansetron—Abdominal pain—Irinotecan—pancreatic cancer	0.000217	0.00114	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000217	0.00114	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000217	0.00114	CcSEcCtD
Ondansetron—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000217	0.00114	CcSEcCtD
Ondansetron—Vomiting—Sunitinib—pancreatic cancer	0.000212	0.00111	CcSEcCtD
Ondansetron—Body temperature increased—Gemcitabine—pancreatic cancer	0.000211	0.00111	CcSEcCtD
Ondansetron—Dysuria—Epirubicin—pancreatic cancer	0.000211	0.00111	CcSEcCtD
Ondansetron—Rash—Sunitinib—pancreatic cancer	0.00021	0.0011	CcSEcCtD
Ondansetron—Dermatitis—Sunitinib—pancreatic cancer	0.00021	0.0011	CcSEcCtD
Ondansetron—Urticaria—Fluorouracil—pancreatic cancer	0.000209	0.0011	CcSEcCtD
Ondansetron—Headache—Sunitinib—pancreatic cancer	0.000209	0.0011	CcSEcCtD
Ondansetron—Syncope—Docetaxel—pancreatic cancer	0.000209	0.0011	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—pancreatic cancer	0.000208	0.00109	CcSEcCtD
Ondansetron—Body temperature increased—Fluorouracil—pancreatic cancer	0.000208	0.00109	CcSEcCtD
Ondansetron—Palpitations—Docetaxel—pancreatic cancer	0.000206	0.00108	CcSEcCtD
Ondansetron—Loss of consciousness—Docetaxel—pancreatic cancer	0.000204	0.00107	CcSEcCtD
Ondansetron—Cough—Docetaxel—pancreatic cancer	0.000203	0.00107	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—pancreatic cancer	0.000203	0.00107	CcSEcCtD
Ondansetron—Hypersensitivity—Irinotecan—pancreatic cancer	0.000202	0.00106	CcSEcCtD
Ondansetron—Convulsion—Docetaxel—pancreatic cancer	0.000202	0.00106	CcSEcCtD
Ondansetron—Drowsiness—Epirubicin—pancreatic cancer	0.000201	0.00105	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000199	0.00105	CcSEcCtD
Ondansetron—Chest pain—Docetaxel—pancreatic cancer	0.000198	0.00104	CcSEcCtD
Ondansetron—Asthenia—Irinotecan—pancreatic cancer	0.000197	0.00104	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000197	0.00103	CcSEcCtD
Ondansetron—Urinary tract infection—Epirubicin—pancreatic cancer	0.000195	0.00103	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—pancreatic cancer	0.000195	0.00102	CcSEcCtD
Ondansetron—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000194	0.00102	CcSEcCtD
Ondansetron—Dry mouth—Docetaxel—pancreatic cancer	0.000194	0.00102	CcSEcCtD
Ondansetron—Asthenia—Gemcitabine—pancreatic cancer	0.000192	0.00101	CcSEcCtD
Ondansetron—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.00019	0.000998	CcSEcCtD
Ondansetron—Anaphylactic shock—Docetaxel—pancreatic cancer	0.00019	0.000997	CcSEcCtD
Ondansetron—Pruritus—Gemcitabine—pancreatic cancer	0.000189	0.000994	CcSEcCtD
Ondansetron—Diarrhoea—Irinotecan—pancreatic cancer	0.000188	0.000987	CcSEcCtD
Ondansetron—Shock—Docetaxel—pancreatic cancer	0.000187	0.000981	CcSEcCtD
Ondansetron—Nervous system disorder—Docetaxel—pancreatic cancer	0.000186	0.000978	CcSEcCtD
Ondansetron—Pruritus—Fluorouracil—pancreatic cancer	0.000186	0.000978	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—pancreatic cancer	0.000186	0.000976	CcSEcCtD
Ondansetron—Tachycardia—Docetaxel—pancreatic cancer	0.000185	0.000973	CcSEcCtD
Ondansetron—Skin disorder—Docetaxel—pancreatic cancer	0.000184	0.000969	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000184	0.000968	CcSEcCtD
Ondansetron—Bradycardia—Epirubicin—pancreatic cancer	0.000184	0.000964	CcSEcCtD
Ondansetron—Diarrhoea—Gemcitabine—pancreatic cancer	0.000183	0.000962	CcSEcCtD
Ondansetron—Dizziness—Irinotecan—pancreatic cancer	0.000182	0.000954	CcSEcCtD
Ondansetron—Haemoglobin—Epirubicin—pancreatic cancer	0.000181	0.000952	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000181	0.000949	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—pancreatic cancer	0.00018	0.000947	CcSEcCtD
Ondansetron—Diarrhoea—Fluorouracil—pancreatic cancer	0.00018	0.000945	CcSEcCtD
Ondansetron—Hypotension—Docetaxel—pancreatic cancer	0.000177	0.000932	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000176	0.000923	CcSEcCtD
Ondansetron—Vomiting—Irinotecan—pancreatic cancer	0.000175	0.000917	CcSEcCtD
Ondansetron—Dizziness—Fluorouracil—pancreatic cancer	0.000174	0.000914	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—pancreatic cancer	0.000174	0.000912	CcSEcCtD
Ondansetron—Rash—Irinotecan—pancreatic cancer	0.000173	0.00091	CcSEcCtD
Ondansetron—Dermatitis—Irinotecan—pancreatic cancer	0.000173	0.000909	CcSEcCtD
Ondansetron—Headache—Irinotecan—pancreatic cancer	0.000172	0.000904	CcSEcCtD
Ondansetron—Paraesthesia—Docetaxel—pancreatic cancer	0.00017	0.000896	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—pancreatic cancer	0.00017	0.000895	CcSEcCtD
Ondansetron—Vomiting—Gemcitabine—pancreatic cancer	0.00017	0.000894	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—pancreatic cancer	0.00017	0.000892	CcSEcCtD
Ondansetron—Dyspnoea—Docetaxel—pancreatic cancer	0.000169	0.000889	CcSEcCtD
Ondansetron—Somnolence—Docetaxel—pancreatic cancer	0.000169	0.000887	CcSEcCtD
Ondansetron—Rash—Gemcitabine—pancreatic cancer	0.000169	0.000886	CcSEcCtD
Ondansetron—Dermatitis—Gemcitabine—pancreatic cancer	0.000169	0.000885	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—pancreatic cancer	0.000168	0.000885	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—pancreatic cancer	0.000168	0.000881	CcSEcCtD
Ondansetron—Headache—Gemcitabine—pancreatic cancer	0.000168	0.00088	CcSEcCtD
Ondansetron—Flushing—Epirubicin—pancreatic cancer	0.000167	0.000879	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—pancreatic cancer	0.000167	0.000879	CcSEcCtD
Ondansetron—Vomiting—Fluorouracil—pancreatic cancer	0.000167	0.000879	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—pancreatic cancer	0.000167	0.000876	CcSEcCtD
Ondansetron—Rash—Fluorouracil—pancreatic cancer	0.000166	0.000871	CcSEcCtD
Ondansetron—Dermatitis—Fluorouracil—pancreatic cancer	0.000166	0.00087	CcSEcCtD
Ondansetron—Headache—Fluorouracil—pancreatic cancer	0.000165	0.000866	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000164	0.000861	CcSEcCtD
Ondansetron—Fatigue—Docetaxel—pancreatic cancer	0.000164	0.00086	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—pancreatic cancer	0.000164	0.000859	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—pancreatic cancer	0.000163	0.000855	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000162	0.000853	CcSEcCtD
Ondansetron—Pain—Docetaxel—pancreatic cancer	0.000162	0.000853	CcSEcCtD
Ondansetron—Constipation—Docetaxel—pancreatic cancer	0.000162	0.000853	CcSEcCtD
Ondansetron—Chills—Epirubicin—pancreatic cancer	0.000162	0.00085	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—pancreatic cancer	0.000161	0.000846	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—pancreatic cancer	0.000161	0.000844	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000158	0.000828	CcSEcCtD
Ondansetron—Erythema—Epirubicin—pancreatic cancer	0.000157	0.000824	CcSEcCtD
Ondansetron—Feeling abnormal—Docetaxel—pancreatic cancer	0.000156	0.000822	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—pancreatic cancer	0.000156	0.000819	CcSEcCtD
Ondansetron—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000155	0.000816	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—pancreatic cancer	0.000155	0.000813	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000155	0.000813	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—pancreatic cancer	0.000155	0.000812	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—pancreatic cancer	0.000151	0.000795	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—pancreatic cancer	0.000151	0.000791	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.00015	0.00079	CcSEcCtD
Ondansetron—Abdominal pain—Docetaxel—pancreatic cancer	0.00015	0.000788	CcSEcCtD
Ondansetron—Body temperature increased—Docetaxel—pancreatic cancer	0.00015	0.000788	CcSEcCtD
Ondansetron—Chills—Doxorubicin—pancreatic cancer	0.00015	0.000786	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—pancreatic cancer	0.000149	0.000783	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—pancreatic cancer	0.000148	0.000777	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000146	0.000765	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—pancreatic cancer	0.000145	0.000763	CcSEcCtD
Ondansetron—Agitation—Epirubicin—pancreatic cancer	0.000144	0.000757	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—pancreatic cancer	0.000143	0.000752	CcSEcCtD
Ondansetron—Malaise—Epirubicin—pancreatic cancer	0.000142	0.000743	CcSEcCtD
Ondansetron—Syncope—Epirubicin—pancreatic cancer	0.000141	0.000739	CcSEcCtD
Ondansetron—Hypersensitivity—Docetaxel—pancreatic cancer	0.00014	0.000735	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—pancreatic cancer	0.000139	0.000728	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—pancreatic cancer	0.000138	0.000724	CcSEcCtD
Ondansetron—Cough—Epirubicin—pancreatic cancer	0.000137	0.000719	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—pancreatic cancer	0.000137	0.000719	CcSEcCtD
Ondansetron—Asthenia—Docetaxel—pancreatic cancer	0.000136	0.000716	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—pancreatic cancer	0.000136	0.000714	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000135	0.000708	CcSEcCtD
Ondansetron—Pruritus—Docetaxel—pancreatic cancer	0.000134	0.000706	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—pancreatic cancer	0.000134	0.000702	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—pancreatic cancer	0.000133	0.000701	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—pancreatic cancer	0.000133	0.000699	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000133	0.000697	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—pancreatic cancer	0.000132	0.000693	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—pancreatic cancer	0.000131	0.000688	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—pancreatic cancer	0.000131	0.000686	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—pancreatic cancer	0.00013	0.000684	CcSEcCtD
Ondansetron—Diarrhoea—Docetaxel—pancreatic cancer	0.00013	0.000682	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—pancreatic cancer	0.000128	0.000674	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000128	0.000673	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000128	0.00067	CcSEcCtD
Ondansetron—Cough—Doxorubicin—pancreatic cancer	0.000127	0.000666	CcSEcCtD
Ondansetron—Shock—Epirubicin—pancreatic cancer	0.000126	0.000662	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—pancreatic cancer	0.000126	0.000661	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—pancreatic cancer	0.000126	0.00066	CcSEcCtD
Ondansetron—Dizziness—Docetaxel—pancreatic cancer	0.000126	0.00066	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—pancreatic cancer	0.000125	0.000657	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—pancreatic cancer	0.000124	0.000653	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—pancreatic cancer	0.000124	0.000649	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—pancreatic cancer	0.000123	0.000647	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000123	0.000645	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—pancreatic cancer	0.000122	0.000642	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—pancreatic cancer	0.000121	0.000635	CcSEcCtD
Ondansetron—Vomiting—Docetaxel—pancreatic cancer	0.000121	0.000634	CcSEcCtD
Ondansetron—Rash—Docetaxel—pancreatic cancer	0.00012	0.000629	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—pancreatic cancer	0.00012	0.000629	CcSEcCtD
Ondansetron—Dermatitis—Docetaxel—pancreatic cancer	0.00012	0.000628	CcSEcCtD
Ondansetron—Headache—Docetaxel—pancreatic cancer	0.000119	0.000625	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000118	0.000622	CcSEcCtD
Ondansetron—Shock—Doxorubicin—pancreatic cancer	0.000117	0.000612	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000116	0.00061	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—pancreatic cancer	0.000116	0.000607	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—pancreatic cancer	0.000115	0.000605	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—pancreatic cancer	0.000115	0.000604	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—pancreatic cancer	0.000114	0.0006	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—pancreatic cancer	0.000114	0.000598	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—pancreatic cancer	0.000111	0.000582	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000111	0.000581	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—pancreatic cancer	0.00011	0.00058	CcSEcCtD
Ondansetron—Constipation—Epirubicin—pancreatic cancer	0.00011	0.000575	CcSEcCtD
Ondansetron—Pain—Epirubicin—pancreatic cancer	0.00011	0.000575	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—pancreatic cancer	0.000106	0.000559	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—pancreatic cancer	0.000106	0.000555	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—pancreatic cancer	0.000106	0.000554	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—pancreatic cancer	0.000105	0.000553	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000105	0.00055	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000102	0.000537	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—pancreatic cancer	0.000102	0.000537	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—pancreatic cancer	0.000102	0.000534	CcSEcCtD
Ondansetron—Pain—Doxorubicin—pancreatic cancer	0.000101	0.000532	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—pancreatic cancer	0.000101	0.000532	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—pancreatic cancer	0.000101	0.000532	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—pancreatic cancer	0.000101	0.000532	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—pancreatic cancer	9.76e-05	0.000513	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—pancreatic cancer	9.69e-05	0.000509	CcSEcCtD
Ondansetron—Hypersensitivity—Epirubicin—pancreatic cancer	9.44e-05	0.000496	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—pancreatic cancer	9.41e-05	0.000494	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—pancreatic cancer	9.37e-05	0.000492	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—pancreatic cancer	9.37e-05	0.000492	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—pancreatic cancer	9.19e-05	0.000483	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—pancreatic cancer	9.06e-05	0.000476	CcSEcCtD
Ondansetron—Diarrhoea—Epirubicin—pancreatic cancer	8.76e-05	0.00046	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—pancreatic cancer	8.73e-05	0.000459	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—pancreatic cancer	8.5e-05	0.000447	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—pancreatic cancer	8.47e-05	0.000445	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—pancreatic cancer	8.38e-05	0.00044	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—pancreatic cancer	8.14e-05	0.000428	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—pancreatic cancer	8.11e-05	0.000426	CcSEcCtD
Ondansetron—Rash—Epirubicin—pancreatic cancer	8.07e-05	0.000424	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—pancreatic cancer	8.07e-05	0.000424	CcSEcCtD
Ondansetron—Headache—Epirubicin—pancreatic cancer	8.02e-05	0.000421	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—pancreatic cancer	7.84e-05	0.000412	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—pancreatic cancer	7.53e-05	0.000396	CcSEcCtD
Ondansetron—Rash—Doxorubicin—pancreatic cancer	7.47e-05	0.000392	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—pancreatic cancer	7.46e-05	0.000392	CcSEcCtD
Ondansetron—Headache—Doxorubicin—pancreatic cancer	7.42e-05	0.00039	CcSEcCtD
Ondansetron—CYP3A7—Metabolism—TYMS—pancreatic cancer	1.47e-05	0.000185	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SMAD4—pancreatic cancer	1.45e-05	0.000183	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AGTR1—pancreatic cancer	1.45e-05	0.000183	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—KRAS—pancreatic cancer	1.44e-05	0.000182	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PRSS1—pancreatic cancer	1.44e-05	0.000182	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	1.44e-05	0.000181	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STK11—pancreatic cancer	1.43e-05	0.00018	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HES1—pancreatic cancer	1.42e-05	0.000179	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TYMP—pancreatic cancer	1.41e-05	0.000178	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TERT—pancreatic cancer	1.41e-05	0.000178	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CD44—pancreatic cancer	1.37e-05	0.000173	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CD44—pancreatic cancer	1.37e-05	0.000172	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.37e-05	0.000172	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.36e-05	0.000171	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HIF1A—pancreatic cancer	1.35e-05	0.00017	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GLP1R—pancreatic cancer	1.35e-05	0.00017	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CD—pancreatic cancer	1.35e-05	0.00017	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TSC2—pancreatic cancer	1.34e-05	0.000169	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GLP1R—pancreatic cancer	1.33e-05	0.000168	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PIK3CA—pancreatic cancer	1.33e-05	0.000167	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—DPYD—pancreatic cancer	1.32e-05	0.000167	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—APOE—pancreatic cancer	1.32e-05	0.000166	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GCG—pancreatic cancer	1.31e-05	0.000166	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—DPYD—pancreatic cancer	1.31e-05	0.000165	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GCG—pancreatic cancer	1.31e-05	0.000165	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCL8—pancreatic cancer	1.31e-05	0.000165	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.29e-05	0.000163	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KDR—pancreatic cancer	1.29e-05	0.000162	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—pancreatic cancer	1.28e-05	0.000162	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	1.26e-05	0.000158	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SMAD4—pancreatic cancer	1.25e-05	0.000158	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ARG2—pancreatic cancer	1.25e-05	0.000157	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	1.25e-05	0.000157	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TERT—pancreatic cancer	1.24e-05	0.000157	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCL8—pancreatic cancer	1.24e-05	0.000156	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—STK11—pancreatic cancer	1.24e-05	0.000156	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—STK11—pancreatic cancer	1.23e-05	0.000155	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.23e-05	0.000155	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HRAS—pancreatic cancer	1.23e-05	0.000155	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NFKBIA—pancreatic cancer	1.23e-05	0.000154	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HES1—pancreatic cancer	1.22e-05	0.000154	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NOTCH1—pancreatic cancer	1.21e-05	0.000153	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—APOE—pancreatic cancer	1.19e-05	0.00015	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.19e-05	0.00015	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HIF1A—pancreatic cancer	1.19e-05	0.00015	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CG—pancreatic cancer	1.19e-05	0.00015	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—NRAS—pancreatic cancer	1.19e-05	0.00015	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TSC2—pancreatic cancer	1.19e-05	0.000149	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGF—pancreatic cancer	1.17e-05	0.000148	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CB—pancreatic cancer	1.17e-05	0.000148	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.17e-05	0.000147	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—APOE—pancreatic cancer	1.16e-05	0.000146	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GLP1R—pancreatic cancer	1.14e-05	0.000144	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KDR—pancreatic cancer	1.14e-05	0.000143	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCL8—pancreatic cancer	1.13e-05	0.000142	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—DPYD—pancreatic cancer	1.12e-05	0.000141	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TYMP—pancreatic cancer	1.09e-05	0.000138	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AKT1—pancreatic cancer	1.08e-05	0.000137	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.08e-05	0.000137	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NFKBIA—pancreatic cancer	1.08e-05	0.000136	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—EGFR—pancreatic cancer	1.08e-05	0.000136	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CG—pancreatic cancer	1.08e-05	0.000136	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TERT—pancreatic cancer	1.07e-05	0.000135	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NOTCH1—pancreatic cancer	1.07e-05	0.000135	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	1.06e-05	0.000134	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TYMS—pancreatic cancer	1.06e-05	0.000134	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TYMS—pancreatic cancer	1.06e-05	0.000134	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.05e-05	0.000133	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CG—pancreatic cancer	1.05e-05	0.000132	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—NRAS—pancreatic cancer	1.05e-05	0.000132	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CD—pancreatic cancer	1.04e-05	0.000131	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PPARG—pancreatic cancer	1.04e-05	0.000131	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGF—pancreatic cancer	1.04e-05	0.00013	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.03e-05	0.00013	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HIF1A—pancreatic cancer	1.03e-05	0.000129	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TSC2—pancreatic cancer	1.02e-05	0.000129	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—KRAS—pancreatic cancer	1.02e-05	0.000129	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.02e-05	0.000128	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APOE—pancreatic cancer	1e-05	0.000126	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KDR—pancreatic cancer	9.81e-06	0.000124	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CD44—pancreatic cancer	9.73e-06	0.000123	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CD44—pancreatic cancer	9.65e-06	0.000122	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EGFR—pancreatic cancer	9.54e-06	0.00012	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CD—pancreatic cancer	9.47e-06	0.000119	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	9.45e-06	0.000119	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PIK3CA—pancreatic cancer	9.38e-06	0.000118	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	9.36e-06	0.000118	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NFKBIA—pancreatic cancer	9.34e-06	0.000118	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GCG—pancreatic cancer	9.33e-06	0.000118	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	9.26e-06	0.000117	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GCG—pancreatic cancer	9.25e-06	0.000117	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NOTCH1—pancreatic cancer	9.25e-06	0.000116	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CD—pancreatic cancer	9.21e-06	0.000116	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	9.12e-06	0.000115	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CB—pancreatic cancer	9.09e-06	0.000115	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CG—pancreatic cancer	9.04e-06	0.000114	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—NRAS—pancreatic cancer	9.04e-06	0.000114	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KRAS—pancreatic cancer	9.01e-06	0.000114	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGF—pancreatic cancer	8.94e-06	0.000113	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GLP1R—pancreatic cancer	8.8e-06	0.000111	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—STK11—pancreatic cancer	8.77e-06	0.000111	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL8—pancreatic cancer	8.74e-06	0.00011	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—STK11—pancreatic cancer	8.69e-06	0.00011	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—pancreatic cancer	8.68e-06	0.000109	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—DPYD—pancreatic cancer	8.66e-06	0.000109	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—APOE—pancreatic cancer	8.65e-06	0.000109	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—APOE—pancreatic cancer	8.63e-06	0.000109	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—pancreatic cancer	8.44e-06	0.000106	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CASP3—pancreatic cancer	8.36e-06	0.000105	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	8.28e-06	0.000104	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	8.25e-06	0.000104	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CD44—pancreatic cancer	8.24e-06	0.000104	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—pancreatic cancer	8.24e-06	0.000104	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	8.21e-06	0.000104	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—pancreatic cancer	8.18e-06	0.000103	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.16e-06	0.000103	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCND1—pancreatic cancer	8.14e-06	0.000103	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	8.07e-06	0.000102	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CTNNB1—pancreatic cancer	8.06e-06	0.000102	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CB—pancreatic cancer	8.03e-06	0.000101	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	8e-06	0.000101	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	7.95e-06	0.0001	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—pancreatic cancer	7.9e-06	9.96e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GCG—pancreatic cancer	7.9e-06	9.96e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.87e-06	9.92e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—pancreatic cancer	7.86e-06	9.9e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CG—pancreatic cancer	7.8e-06	9.83e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	7.79e-06	9.81e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	7.78e-06	9.81e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL8—pancreatic cancer	7.71e-06	9.72e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—pancreatic cancer	7.67e-06	9.66e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—pancreatic cancer	7.66e-06	9.66e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TYMS—pancreatic cancer	7.54e-06	9.51e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARG—pancreatic cancer	7.53e-06	9.49e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARG—pancreatic cancer	7.52e-06	9.47e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TYMS—pancreatic cancer	7.48e-06	9.42e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—pancreatic cancer	7.45e-06	9.39e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—STK11—pancreatic cancer	7.43e-06	9.36e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP3—pancreatic cancer	7.38e-06	9.3e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SRC—pancreatic cancer	7.29e-06	9.18e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCND1—pancreatic cancer	7.19e-06	9.05e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	7.15e-06	9.01e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—pancreatic cancer	7.13e-06	8.99e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CTNNB1—pancreatic cancer	7.12e-06	8.97e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—pancreatic cancer	7.1e-06	8.94e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STAT3—pancreatic cancer	7.03e-06	8.86e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NRAS—pancreatic cancer	7.01e-06	8.83e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—pancreatic cancer	6.98e-06	8.79e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.97e-06	8.79e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—pancreatic cancer	6.94e-06	8.74e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	6.93e-06	8.73e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CD—pancreatic cancer	6.86e-06	8.64e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	6.85e-06	8.63e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—pancreatic cancer	6.77e-06	8.53e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	6.66e-06	8.39e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	6.61e-06	8.33e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MYC—pancreatic cancer	6.53e-06	8.23e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TGFB1—pancreatic cancer	6.51e-06	8.21e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SRC—pancreatic cancer	6.43e-06	8.1e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	6.43e-06	8.1e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TYMS—pancreatic cancer	6.39e-06	8.05e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—pancreatic cancer	6.39e-06	8.05e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	6.37e-06	8.03e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CD44—pancreatic cancer	6.36e-06	8.02e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—pancreatic cancer	6.26e-06	7.89e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STAT3—pancreatic cancer	6.2e-06	7.82e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	6.2e-06	7.82e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NRAS—pancreatic cancer	6.19e-06	7.8e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	6.14e-06	7.74e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APOE—pancreatic cancer	6.14e-06	7.73e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GCG—pancreatic cancer	6.1e-06	7.69e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOE—pancreatic cancer	6.08e-06	7.66e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	6.03e-06	7.6e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	6.02e-06	7.59e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	5.99e-06	7.54e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CB—pancreatic cancer	5.98e-06	7.53e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	5.97e-06	7.52e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—pancreatic cancer	5.92e-06	7.47e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—pancreatic cancer	5.91e-06	7.45e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	5.84e-06	7.36e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MYC—pancreatic cancer	5.76e-06	7.26e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.76e-06	7.26e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TGFB1—pancreatic cancer	5.75e-06	7.24e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—STK11—pancreatic cancer	5.73e-06	7.23e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—pancreatic cancer	5.64e-06	7.1e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SRC—pancreatic cancer	5.55e-06	7e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	5.54e-06	6.99e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	5.54e-06	6.98e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	5.49e-06	6.92e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	5.41e-06	6.81e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—pancreatic cancer	5.36e-06	6.76e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	5.35e-06	6.75e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARG—pancreatic cancer	5.34e-06	6.73e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	5.34e-06	6.73e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—pancreatic cancer	5.33e-06	6.71e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARG—pancreatic cancer	5.3e-06	6.68e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOE—pancreatic cancer	5.2e-06	6.55e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—pancreatic cancer	5.17e-06	6.51e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—pancreatic cancer	5.16e-06	6.5e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	5.13e-06	6.46e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	5.03e-06	6.34e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MYC—pancreatic cancer	4.97e-06	6.27e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	4.96e-06	6.25e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.93e-06	6.22e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.92e-06	6.2e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CA—pancreatic cancer	4.89e-06	6.17e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	4.87e-06	6.13e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	4.87e-06	6.13e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	4.83e-06	6.08e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—pancreatic cancer	4.73e-06	5.96e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	4.69e-06	5.91e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	4.6e-06	5.79e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	4.53e-06	5.71e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARG—pancreatic cancer	4.53e-06	5.71e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—pancreatic cancer	4.53e-06	5.7e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	4.24e-06	5.35e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	4.22e-06	5.32e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	4.21e-06	5.3e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—pancreatic cancer	4.2e-06	5.3e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—pancreatic cancer	4.17e-06	5.25e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	4.12e-06	5.2e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—pancreatic cancer	4.11e-06	5.18e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—pancreatic cancer	4.09e-06	5.15e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOE—pancreatic cancer	4.01e-06	5.06e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—pancreatic cancer	4e-06	5.04e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	3.91e-06	4.92e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.67e-06	4.62e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CA—pancreatic cancer	3.65e-06	4.59e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	3.64e-06	4.58e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—pancreatic cancer	3.63e-06	4.58e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.62e-06	4.56e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	3.59e-06	4.53e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—pancreatic cancer	3.56e-06	4.49e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.49e-06	4.4e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	3.45e-06	4.35e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	3.18e-06	4.01e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—pancreatic cancer	3.11e-06	3.91e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—pancreatic cancer	2.98e-06	3.75e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—pancreatic cancer	2.97e-06	3.74e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.77e-06	3.5e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.75e-06	3.46e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.59e-06	3.26e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.56e-06	3.23e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.4e-06	3.02e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	2.19e-06	2.76e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.11e-06	2.66e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—pancreatic cancer	2.09e-06	2.64e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.79e-06	2.26e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.69e-06	2.13e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.38e-06	1.74e-05	CbGpPWpGaD
